

Special Issue

Advances in Multiple Sclerosis Research—Series II

Message from the Guest Editors

Designing immunotherapeutics, drugs, and anti-inflammatory reagents has been at the forefront of autoimmune research, in particular for multiple sclerosis, for over 20 years. Delivery methods that are used to modulate effective and long-lasting immune responses have been the major focus. This Special Issue will focus on delivery methods to be used for vaccines, immunotherapeutic approaches, drug design, and anti-inflammatories and their outcomes in preclinical studies and clinical trials. We invite you read the Special Issue "Advances in Multiple Sclerosis Research—Series I" at mdpi.com/si/30935

Guest Editors

Prof. Dr. John Matsoukas
NewDrug, Patras Science Park, Patras, Greece

Prof. Dr. Vasso Apostolopoulos
Institute for Health and Sport, Victoria University, Melbourne, VIC, Australia

Deadline for manuscript submissions

closed (28 February 2022)



Brain Sciences

an Open Access Journal
by MDPI

Impact Factor 2.7
CiteScore 4.8
Indexed in PubMed



mdpi.com/si/53746

Brain Sciences
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
brainsci@mdpi.com

[mdpi.com/journal/
brainsci](https://mdpi.com/journal/brainsci)





Brain Sciences

an Open Access Journal
by MDPI

Impact Factor 2.7
CiteScore 4.8
Indexed in PubMed



[mdpi.com/journal/
brainsci](https://mdpi.com/journal/brainsci)



About the Journal

Message from the Editor-in-Chief

You are invited to contribute a research article or a comprehensive review for consideration and publication in *Brain Sciences* (ISSN 2076-3425). *Brain Sciences* is an open access, peer-reviewed scientific journal that publishes original articles, critical reviews, research notes, and short communications on neuroscience. The scientific community and the general public can access the content free of charge as soon as it is published.

Editor-in-Chief

Prof. Dr. Stephen D. Meriney

Department of Neuroscience, University of Pittsburgh, Pittsburgh, PA
15260, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, PSYINDEX, PsycInfo, CAPlus / SciFinder, and other databases.

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 12.9 days after submission; acceptance to publication is undertaken in 2.5 days (median values for papers published in this journal in the first half of 2024).

Recognition of Reviewers:

reviewers who provide timely, thorough peer-review reports receive vouchers entitling them to a discount on the APC of their next publication in any MDPI journal, in appreciation of the work done.